DNAprint Genomics (DNAG)

[IVRT]

DNAPrint genomics, Inc. Welcomes Ramin Mirhashemi,
M.D.

DALLAS & CALGARY, Alberta--(BUSINESS WIRE)--Sept. 28, 2000-- DNAPrint genomics, Inc.
(Pink Sheets:DNAP), a Sarasota, Florida-based genomics company, announced today that it has
added Ramin Mirhashemi, M.D. to its Scientific Advisory Board.

Dr. Mirhashemi, currently serves as Director of the University of Miami/JMH/Sylvester Cancer Center
and Familial Ovarian/Breast Cancer Center, in Miami, Florida. He is an assistant Professor,
Department of Obstetrics and Gynecology and a Clinical Fellow in Gynecologic Oncology at the
University of Miami School of Medicine. Dr. Mirhashemi is the recipient of the prestigious
ACOG/Ortho-McNeil Fellowship Grant, and has accumulated 8 different honors and awards as a
Gynecologic Oncologist and Surgeon.

CEO/CSO Dr. Tony Frudakis said, "Dr. Mirhashemi is an extremely valuable addition to our Scientific
Advisory Board. His experience and expertise with biopharmaceutical partners and
experimental/clinical trial study design will help guide the structure and placement of our cancer
pharmacogenomics studies."

About DNAPrint genomics

DNAPrint genomics, Inc. is developing complex genetic analytics and knowledge resources for next
generations personalized medicine. The company provides practitioners of genomic research and
personalized medicine with a comprehensive system for complex trait dissection and patient
classification. DNAPrint genomics, Inc. was founded by a group of scientists with research and
commercial experience in high-level mathematical modeling, programming and molecular genetics. For
more information about the company, please visit www.stocktribe.com

Except for factual statements made herein, the information contained in this press release consists of
forward-looking statements that involve risks and uncertainties. The Company's actual results could
differ materially from those contained in such statements. Factors that could cause or contribute to such
differences include unexpected shortages of critical components, rescheduling or cancellation of
customer orders, the timing and market acceptance of new product introductions by the Company and
its competitors, and general competition and price pressures in the marketplace.

Stocktribe.com has not been compensated for this summary, nor do we hold a position in this
company.

Contact:

DNAPrint genomics, Inc.
Craig Hall, 941/923-1949
or
Stocktribe.com
Mike Hale, 403/228-3685
Website: (www.stocktribe.com)

http://www.clearstation.com/cgi-bin/bbs?post_id=1679654&Refer=http://www.clearstation.com/cgi-bin/symbol_search%253fcmd%253dsearch%2526string%253ddnap